An Evaluation of μ-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol Dependence | Zendy

Raymond F. Anton | Zendy; Gábor Oroszi | Zendy; Stephanie S. O’Malley | Zendy; David Couper | Zendy; Robert M. Swift | Zendy; Helen M. Pettinati | Zendy; David Goldman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

An Evaluation of μ-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol Dependence

Author(s) -

Raymond F. Anton,

Gábor Oroszi,

Stephanie S. O’Malley,

David Couper,

Robert M. Swift,

Helen M. Pettinati,

David Goldman

Publication year - 2008

Publication title -

archives of general psychiatry

Language(s) - English

Resource type - Journals

eISSN - 1538-3636

pISSN - 0003-990X

DOI - 10.1001/archpsyc.65.2.135

Subject(s) - naltrexone , placebo , alcohol dependence , medicine , odds ratio , opioid , confidence interval , genotype , pharmacogenetics , alcohol use disorder , allele , psychology , alcohol , pharmacology , receptor , biology , genetics , gene , pathology , biochemistry , alternative medicine

Naltrexone hydrochloride treatment for alcohol dependence works for some individuals but not for everyone. Asn40Asp, a functional polymorphism of the mu-opioid receptor gene (OPRM1), might predict naltrexone response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research